This combination nebuliser solution is used for the management of reversible bronchospasm associated with obstructive airway diseases in patients who need more than one bronchodilator for adequate relief.

This inhalation solution contains two active bronchodilators: Salbutamol Sulphate and Ipratropium Bromide. Salbutamol Sulphate is a selective beta₂-adrenergic agonist that relaxes airway smooth muscles from the trachea to the terminal bronchioles and helps prevent bronchoconstriction. Ipratropium Bromide is an anticholinergic agent that works by blocking acetylcholine-mediated reflexes through inhibition of muscarinic receptors in bronchial smooth muscle. This action reduces intracellular cyclic GMP levels and leads to bronchodilation. The effect of Ipratropium is mainly localized in the lungs with minimal systemic absorption. The combination ensures a dual mechanism of action on beta₂-adrenergic and muscarinic receptors, producing enhanced bronchodilation compared to either agent alone without increasing adverse effects.

Ipratropium Bromide is rapidly absorbed following inhalation, with systemic bioavailability estimated to be less than 10%. Approximately 46% of the administered dose is excreted via the kidneys after intravenous use. The terminal elimination half-life is about 1.6 hours, while the overall elimination half-life including metabolites is around 3.6 hours. It does not cross the blood-brain barrier.

Salbutamol Sulphate is quickly and completely absorbed after inhalation or oral administration. Peak plasma levels are reached within 3 hours, and most of the drug is excreted unchanged in the urine within 24 hours. Its elimination half-life is approximately 4 hours. Salbutamol can cross the blood-brain barrier, reaching about 5% of plasma concentration levels.

Studies indicate that co-administration via nebulisation does not increase systemic absorption of either drug; the enhanced effect is due to their combined local action in the lungs.

Salbutamol sulfate & Ipratropium bromide solution for inhalation in ampoule may be administered from a suitable nebulizer or an intermittent positive pressure ventilator.

• Adults (including elderly): Use one 3 ml ampoule in the nebulizer four times a day. Two additional treatments may be used per day, if needed.
• Children: Use and dose must be determined by doctor.

Patients should be advised to consult a doctor or the nearest hospital immediately in the case of acute or rapidly worsening dyspnoea if additional inhalations do not produce an adequate improvement.

• Step 1: Twist off the top of the ampoule. Be careful to hold the ampoule upright.
• Step 2: Squeeze the desired amount of the nebulizer solution into the nebulizer chamber.
• Step 3: If dilution is needed follow the physician’s direction.

Concurrent use of other beta-mimetic agents, systemically absorbed anticholinergics, or xanthine derivatives may enhance the risk of side effects. Beta-agonist–induced hypokalaemia may be further increased when used together with xanthine derivatives, glucocorticosteroids, or diuretics, particularly in patients with severe airway obstruction.

Hypokalaemia can increase the risk of cardiac arrhythmias, especially in patients receiving digoxin; therefore, monitoring of serum potassium levels is recommended in such cases.

A reduction in bronchodilator response may occur if beta-blockers are used at the same time. Beta-adrenergic agonists should be used cautiously in patients taking monoamine oxidase inhibitors or tricyclic antidepressants, as their effects may be potentiated.

Inhalation of halogenated hydrocarbon anaesthetics such as halothane, trichloroethylene, and enflurane may increase the risk of cardiovascular side effects associated with beta-agonists.

This solution is contraindicated in patients with hypertrophic obstructive tachyarrhythmia and in those with known hypersensitivity to atropine or its derivatives, or to any component of the formulation.

Like other beta-agonist–containing products, this solution may cause fine skeletal muscle tremor and nervousness. Less commonly, tachycardia, dizziness, palpitations, and headache may occur, particularly in sensitive individuals.

Prolonged or high-dose use of beta₂-agonists may lead to significant hypokalaemia.

As with other inhalation therapies, cough, local irritation, and occasionally bronchospasm may occur. Other possible effects include nausea, vomiting, sweating, weakness, and muscle cramps. Rarely, changes in blood pressure and cardiac arrhythmias may develop, especially at higher doses.
Psychological effects have been reported in some cases with beta-mimetic inhalation therapy.

Common anticholinergic side effects include dry mouth and voice changes. Rare ocular complications such as mydriasis, increased intraocular pressure, angle-closure glaucoma, and eye pain may occur if the aerosol comes into contact with the eyes. Gastrointestinal motility disturbances and urinary retention are rare and usually reversible.

Pregnancy category C. Animal studies with Salbutamol Sulphate have shown teratogenic effects; however, adequate human data are lacking. No clear evidence of fetal abnormalities has been reported in pregnant women using albuterol. This solution should be used during pregnancy only if the expected benefit outweighs the potential risk. Caution is advised before delivery due to the inhibitory effect of Salbutamol on uterine contractions.

Both Salbutamol Sulphate and Ipratropium Bromide may be excreted in breast milk, although the extent and effects on infants are not well established. While inhalation reduces systemic exposure, caution should still be exercised when administering to breastfeeding mothers.

In cases of acute or rapidly worsening shortness of breath, immediate medical consultation is necessary. Rare cases of hypersensitivity reactions such as urticaria, angioedema, rash, bronchospasm, or swelling of the oropharynx may occur following use of this solution.

Overdose effects are mainly related to Salbutamol, as Ipratropium Bromide has low systemic absorption.

Symptoms may include tachycardia, chest pain, high or low blood pressure, palpitations, tremor, widened pulse pressure, arrhythmias, and flushing.

Management includes supportive care with sedatives or tranquillisers; in severe cases, intensive care may be required. Beta₁-selective blockers may be used cautiously as antidotes, keeping in mind the risk of bronchospasm, especially in asthma patients.

Combined bronchodilators

Store below 30°C, protected from light and moisture. Keep out of the reach of children.